Drug Conjugation Technology definition

Drug Conjugation Technology means chemical compositions and methods that are useful to attach cytotoxins or cytostatic compounds to Antibodies, including the composition and methods of making and using cytotoxic or cytostatic compounds, as well as compositions and methods useful for attaching the foregoing cytotoxic or cytostatic compounds to Antibodies.

Drug Conjugation Technology means (a) methods that are useful in attaching the [ * ] or [ * ] to antibodies using the linker [ * ] or [ * ], including the composition and methods of making and using such cytotoxic compound [ * ] or [ * ] and (b) any related assays and methods SGI provided to Genmab pursuant to the Research Program or provides to Genmab pursuant to Section 4.4 or the Collaboration Program, in each case to the extent Controlled by SGI.

Drug Conjugation Technology means drug conjugation chemistry owned or controlled by SGI, [*] and linker technology for attaching drugs to Antibodies that is the subject matter of the Licensed Patents and SGI Know-How.

Examples of Drug Conjugation Technology in a sentence

• The Collaboration Agreement makes clear that technology wholly unrelated to Drug Conjugation Technology is not an Improvement.

• Daiichi Sankyo is entitled to a declaratory judgment, pursuant to 28 U.S.C.§ 2201, declaring that Daiichi Sankyo has ownership rights to the Patents and Patent Applications at Issue, and SGI has no ownership interest in the Patents and Patent Applications at Issue as they do not constitute Improvements of Drug Conjugation Technology as defined in the Collaboration Agreement.

• Daiichi Sankyo seeks a judgment declaring its ownership rights to the Patents and Patent Applications at Issue and affirming that SGI does not have any ownership rights because the Patents and Patent Applications at Issue are not Improvements of Drug Conjugation Technology as defined in the now-expired Collaboration Agreement Daiichi Sankyo had with SGI.

• SGI alleges that unrelated ADC technology developed by Daiichi Sankyo— e.g., technology that does not use or relate to the Drug Conjugation Technology as defined by the Collaboration Agreement—is an Improvement under the Collaboration Agreement.

• In that letter, Daiichi Sankyo disputed the claims made in SGI’s letter dated August 19, 2019, and noted that it did not understand how that subset of the Patents and Patent Applications at Issue constitutes an Improvement of Drug Conjugation Technology as defined in the Collaboration Agreement.

More Definitions of Drug Conjugation Technology

Drug Conjugation Technology means (a) cytotoxins or cytostatic

Drug Conjugation Technology means (a) [***] compounds such as [***] and [***] and certain [***] and [***] thereof, and methods of making and using such [***] compounds (b) compositions and methods useful for attaching the foregoing [***] compounds to [***] and (c) any related assays and methods SGI provides to Licensee pursuant to the Research Program.

Drug Conjugation Technology means drug conjugation chemistry owned or controlled by SGI, including [***] and linker technology for attaching drugs to Antibodies that is the subject matter of the Licensed Patents and SGI Know-How.

Drug Conjugation Technology means chemical compositions and methods that are useful to attach [***] compounds to Antibodies, including without limitation the composition and methods of making and using [***] compounds such as [***] and [***] and [***] thereof, as well as compositions and methods useful for attaching [***] or [***] to [***].

Drug Conjugation Technology means (a) cytotoxins or cytostatic compounds

Drug Conjugation Technology means chemical compositions and methods, including methods of manufacture, that are Controlled by SGI and that are useful to attach cytotoxins or cytostatic compounds to Antibodies, including the composition and methods of making and using cytotoxic or cytostatic compounds, as well as compositions and methods useful for attaching the foregoing cytotoxic or cytostatic compounds to Antibodies. “Effective Date” means the date set forth in the first line of this Agreement. “EMEA” means the European Medicines Agency and any successor agency(ies) thereto. “Events of Force Majeure” has the meaning set forth in Article 19. “Exclusive Antigen” means collectively, the First Exclusive Antigen, the Second Exclusive Antigen and the Third Exclusive Antigen, but specifically excluding any Collaboration Antigen. “Exclusive License” has the meaning set forth in Section 10.1.2. -9-

Drug Conjugation Technology means Drug Conjugation Materials and uses thereof, including [***], and methods for producing Drug Conjugation Materials and attaching Drug Conjugation Materials to [***] and the [***], and uses thereof.